Ken Griffin Sarepta Therapeutics, Inc. Transaction History

Citadel Advisors LLC

$509 Billion
Q1 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Sarepta Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 331,100 shares of SRPT stock, worth $52.3 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

331,100

Previous 396,800 16.56%

Holding current value

$52.3 Million

Previous $38.3 Million 12.02%

% of portfolio

0.01%

Previous 0.01%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$93.7 - $141.53 $16.9 Million - $25.5 Million	180,347 Added 13.43%	1,523,077 $197 Million
Q4 2023 Feb 14, 2024	BUY	$67.31 - $124.76 $7.72 Million - $14.3 Million	114,756 Added 9.35%	1,342,730 $129 Million
Q3 2023 Nov 14, 2023	BUY	$102.5 - $123.59 $34.6 Million - $41.7 Million	337,261 Added 37.86%	1,227,974 $149 Million
Q2 2023 Aug 14, 2023	BUY	$106.4 - $157.19 $67.8 Million - $100 Million	637,299 Added 251.49%	890,713 $102 Million
Q1 2023 May 15, 2023	SELL	$117.53 - $155.99 $17.9 Million - $23.7 Million	-152,067 Reduced 37.5%	253,414 $34.9 Million

Q4 2022 Feb 14, 2023	BUY	$100.86 - $132.13 $30.6 Million - $40.1 Million	303,359 Added 297.06%	405,481 $52.5 Million
Q3 2022 Nov 14, 2022	SELL	$75.71 - $119.24 $35.7 Million - $56.2 Million	-471,201 Reduced 82.19%	102,122 $11.3 Million
Q2 2022 Aug 15, 2022	SELL	$62.69 - $88.44 $1.38 Million - $1.94 Million	-21,965 Reduced 3.69%	573,323 $43 Million
Q1 2022 May 16, 2022	BUY	$63.15 - $90.42 $17.6 Million - $25.2 Million	278,861 Added 88.13%	595,288 $46.5 Million
Q4 2021 Feb 14, 2022	SELL	$77.28 - $99.42 $35.2 Million - $45.3 Million	-455,377 Reduced 59.0%	316,427 $28.5 Million
Q3 2021 Nov 15, 2021	BUY	$65.97 - $92.48 $3.92 Million - $5.5 Million	59,445 Added 8.34%	771,804 $71.4 Million
Q2 2021 Aug 16, 2021	BUY	$69.38 - $86.75 $32.4 Million - $40.5 Million	466,488 Added 189.73%	712,359 $55.4 Million
Q1 2021 May 17, 2021	BUY	$72.25 - $168.95 $16.5 Million - $38.7 Million	228,789 Added 1339.36%	245,871 $18.3 Million
Q4 2020 Feb 16, 2021	SELL	$125.56 - $178.74 $15.3 Million - $21.8 Million	-122,029 Reduced 87.72%	17,082 $2.91 Million
Q3 2020 Nov 16, 2020	BUY	$127.12 - $172.34 $9.57 Million - $13 Million	75,309 Added 118.04%	139,111 $19.5 Million
Q2 2020 Aug 14, 2020	SELL	$93.0 - $171.7 $6.37 Million - $11.8 Million	-68,500 Reduced 51.78%	63,802 $10.2 Million
Q1 2020 May 15, 2020	BUY	$82.38 - $131.64 $4.17 Million - $6.66 Million	50,585 Added 61.9%	132,302 $12.9 Million
Q4 2019 Feb 14, 2020	SELL	$76.53 - $135.58 $19.1 Million - $33.9 Million	-249,913 Reduced 75.36%	81,717 $10.5 Million
Q3 2019 Nov 14, 2019	BUY	$72.81 - $156.91 $23 Million - $49.6 Million	316,262 Added 2057.93%	331,630 $25 Million
Q2 2019 Aug 14, 2019	SELL	$112.21 - $151.95 $17.4 Million - $23.6 Million	-155,342 Reduced 91.0%	15,368 $2.34 Million
Q1 2019 May 15, 2019	BUY	$106.67 - $151.68 $17.9 Million - $25.4 Million	167,483 Added 5190.05%	170,710 $0
Q4 2018 Feb 14, 2019	SELL	$97.32 - $148.76 $27.6 Million - $42.2 Million	-283,984 Reduced 98.88%	3,227 $352,000
Q3 2018 Nov 13, 2018	SELL	$115.31 - $161.51 $17.4 Million - $24.4 Million	-151,103 Reduced 34.47%	287,211 $0
Q2 2018 Aug 10, 2018	BUY	$71.74 - $153.69 $28 Million - $59.9 Million	389,927 Added 805.85%	438,314 $0
Q1 2018 May 11, 2018	SELL	$54.02 - $82.27 $21.7 Million - $33 Million	-401,315 Reduced 89.24%	48,387 $3.59 Million
Q4 2017 Feb 09, 2018	SELL	$47.64 - $56.75 $75.5 Million - $90 Million	-1,585,488 Reduced 77.9%	449,702 $25 Million
Q3 2017 Nov 09, 2017	BUY	$35.73 - $47.15 $72.7 Million - $96 Million	2,035,190	2,035,190 $92.3 Million

Others Institutions Holding SRPT

# of Institutions

470

Shares Held

79.3M

Call Options Held

4.23M

Put Options Held

1.21M

View Full List

About Sarepta Therapeutics, Inc.

Ticker SRPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,567,904
Market Cap $13.8B
Description
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...

More about SRPT

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account